1stOncology™: Cancer Intelligence Service – Page 7803 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Theseus Pharmaceuticals to Present Preclinical Data Characterizing Next-Generation Epidermal Growth Factor Receptor (EGFR) Inhibitors at the 2022 American Association for Cancer Research (AACR) Annual Meeting

On March 8, 2022 Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, reported that the Company will present a poster highlighting the characterization of potent and selective next-generation EGFR inhibitors at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) 2022 Annual Meeting, being held April 8-13, 2022 in New Orleans, Louisiana (Press release, Theseus Pharmaceuticals, MAR 8, 2022, View Source [SID1234609723]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Presentation details:
Abstract Title: Discovery of potent and selective next-generation EGFR inhibitors with activity against single, double, and triple mutant EGFR variants including T790M and C797S
Abstract Number: 3342
Presenter: Wei-Sheng Huang, Ph.D., Vice President of Chemistry
Session Date and Time: Tuesday, April 12th, 1:30pm-5pm CT

The presentation will detail the characterization of compounds that potently inhibit the kinase activity, both in vitro and in vivo, of single, double, and triple mutant EGFR variants including T790M and C797S, with selectivity over wild-type EGFR and the ability to penetrate the central nervous system. These variants comprise all major classes of EGFR activating and resistance mutations that contribute to later-line clonal heterogeneity in patients who have been failed by current approved therapies.

EGFR activating mutations are observed in 10-50 percent of non-small cell lung cancer (NSCLC) patients and are initially sensitive to first, second, and third generation EGFR inhibitors. However, on-target resistance is observed in a substantial percentage of patients, with T790M and C797S mutations observed most frequently.

Omega Therapeutics to Present Preclinical Data for OTX-2002 at the American Association for Cancer Research Annual Meeting 2022

On March Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing platform, reported that it will present preclinical data for OTX-2002, the Company’s lead drug candidate for the treatment of hepatocellular carcinoma (HCC), at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022, taking place in New Orleans, Louisiana, April 8-13, 2022 (Press release, Omega Therapeutics, MAR 8, 2022, View Source [SID1234609722]).

"These preclinical data highlight the potential of epigenetic modulation of the c-MYC (MYC) oncogene as a promising new approach for the treatment of hepatocellular carcinoma (HCC), where MYC over expression is associated with aggressive disease in up to 70% of HCC cases," said Mahesh Karande, President and Chief Executive Officer of Omega Therapeutics. "While MYC represents an attractive therapeutic target, it has historically been considered undruggable, due to the consistent failure of current modalities to inhibit MYC directly or indirectly. We look forward to sharing these data that support the potential of epigenetic modulation using our platform to systematically control the underlying biology of gene expression and remain on track to file an Investigational New Drug application for OTX-2002 in the first half of 2022."

Details for the AACR (Free AACR Whitepaper) Annual Meeting 2022 poster presentation are as follows:

Title: Epigenetic modulation of the MYC oncogene as a potential novel therapy for HCC
Abstract #: 2629
Date and Time: Tuesday, April 12, 2022 at 9:00 a.m. through 12:30 p.m. CDT

The poster will be posted to our website at View Source at the same time as the presentation.

About OTX-2002

OTX-2002 is a first-in-class Omega Epigenomic Controller in development for the treatment of hepatocellular carcinoma (HCC). OTX-2002 is designed to modulate levels of c-MYC (MYC) expression by utilizing targeted mRNA-encoded proteins to mediate epigenetic regulation while potentially overcoming MYC auto regulation. The MYC oncogene is associated with aggressive disease in up to ~70% of patients with HCC. Omega is currently evaluating OTX-2002 in Investigational New Drug (IND)-enabling studies.

Arcellx Announces Pre-Clinical Data Presentation for ACLX-002, a Novel CD123-targeted Universal CAR-T Cell Therapy for Relapsed or Refractory Acute Myeloid Leukemia at the American Association for Cancer Research Annual Meeting 2022

On March 8, 2022 Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, reported the upcoming presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022 of pre-clinical data for ACLX-002, a novel CD123-targeted universal CAR-T cell therapy for relapsed or refractory Acute Myeloid Leukemia (AML) (Press release, Arcellx, MAR 8, 2022, View Source [SID1234609721]). ACLX-002 can be activated in a dose dependent manner in vivo with soluble protein adapters allowing for controllability and adaptability to address intra-and inter-patient disease heterogeneity and off-target antigen expression that are often associated with serious dose-limiting adverse events in AML.

Details of the Presentation are as Follows:

Session Category: Immunology
Session Title: Adoptive Cell Therapy 2
Session Date and Time: Sunday, April 10, 2022, 1:30 PM – 5:00 PM
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 37
Poster Board Number: 22
Permanent Abstract Number: 587

HotSpot Therapeutics to Present Pre-Clinical Data on CBL-B Program at American Association for Cancer Research Annual Meeting 2022

On March 8, 2022 HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of first- and best-in-class allosteric therapies targeting regulatory sites on proteins referred to as "natural hotspots," reported it will present additional pre-clinical data on the company’s CBL-B program in a poster presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022, taking place April 8-13, 2022, in New Orleans, LA (Press release, HotSpot Therapeutics, MAR 8, 2022, View Source [SID1234609720]).

Presentation details are as follows:

Title: A novel allosteric CBL-B inhibitor with differentiated immune enhancing activity in preclinical models
Session Category: Immunology
Session Title: Immune Checkpoints
Session Date and Time: Sun., Apr. 10, 2022, 1:30-5:00 PM ET
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 38
Poster Board Number: 8
Abstract Number: 598

Schrödinger To Present New Preclinical Data From Its Wee1 Inhibitor Program At AACR Annual Meeting 2022

On March 8, 2022 Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, reported that new preclinical data on its small-molecule Wee1 inhibitors will be presented during a poster session at the American Association of Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting taking place in New Orleans, Louisiana, April 8-13, 2022 (Press release, Schrodinger, MAR 8, 2022, View Source [SID1234609719]).

Wee1 is a gatekeeper checkpoint kinase that prevents cellular progression through the cell cycle, allowing time for DNA repair before cell division takes place. Inhibition of Wee1 allows for accumulation of DNA damage, triggering DNA breakage and apoptosis in tumor cells. Data from third party clinical studies are showing promising anti-tumor activity in solid tumors, including ovarian and uterine cancer. Schrödinger has identified multiple highly selective Wee1 inhibitors with optimized physicochemical properties that show strong pharmacodynamic responses and anti-tumor activity in preclinical models. This potentially best-in-class profile may position these structurally distinct Wee1 inhibitors for applications both as monotherapy and as combination therapy with other agents. Schrödinger expects to select a Wee1 development candidate later this year.

Details of the poster presentation are as follows:

Title: Discovery of potent, selective, and orally available Wee1 inhibitors that demonstrate increased DNA damage and mitosis in tumor cells leading to tumor regression in vivo
Abstract number: 2570
Date & time: Tuesday, April 12, 9:00 a.m – 12:30 p.m. CDT
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 21